Q4 25 EPS
$1.25
BEAT +0.81%
Est. $1.24
Q4 25 Revenue
$1.10B
MISS 5.22%
Est. $1.16B
vs S&P Since Q4 25
-9.1%
TRAILING MARKET
ALNY -3.4% vs S&P +5.7%
Full Year 2025 Results
FY 25 EPS
$5.08
BEAT +6.03%
Est. $4.79
FY 25 Revenue
$3.71B
MISS 1.60%
Est. $3.77B
Market Reaction
Did ALNY Beat Earnings? Q4 2025 Results
Alnylam Pharmaceuticals delivered a mixed but broadly compelling Q4 2025, posting a narrow earnings beat alongside a revenue miss that did little to obscure the company's broader transformation. Non-GAAP diluted EPS came in at $1.25, edging past the … Read more Alnylam Pharmaceuticals delivered a mixed but broadly compelling Q4 2025, posting a narrow earnings beat alongside a revenue miss that did little to obscure the company's broader transformation. Non-GAAP diluted EPS came in at $1.25, edging past the $1.24 consensus estimate by 0.81%, while quarterly revenue of $1.10 billion fell 5.22% short of the $1.16 billion Wall Street had expected, even as it surged 85.0% year-over-year. The engine behind that growth was unmistakable: AMVUTTRA net product revenues exploded 189% to $826.59 million in the quarter, driven by accelerating patient demand following its landmark U.S. Approval for ATTR cardiomyopathy, a launch that also helped Alnylam achieve full-year GAAP profitability for the first time. The company's FDA approval of additional pipeline assets has further reinforced its standing as a leader in RNAi therapeutics. Looking ahead, Alnylam guided 2026 total net product revenues of $4.90 billion to $5.30 billion, representing growth of 64% to 77%, anchored by TTR franchise revenues projected at $4.40 billion to $4.70 billion.
Key Takeaways
- • Landmark U.S. approval of AMVUTTRA for ATTR-CM driving 189% Q4 AMVUTTRA revenue growth
- • Rapidly increasing patient demand for AMVUTTRA, mainly in ATTR-CM in the U.S.
- • Total TTR franchise revenue growth of 151% in Q4 and 103% for the full year
- • Continued growth in GIVLAARI and OXLUMO patient bases
- • Royalty revenue growth of 73% in Q4 and 90% full year driven by increasing Leqvio sales by Novartis
- • Achievement of both GAAP and non-GAAP full-year profitability
ALNY YoY Financials
Q4 2025 vs Q4 2024, source: SEC Filings
ALNY Revenue by Segment
With YoY comparisons, source: SEC Filings
“2025 was a year of key accomplishments for Alnylam, highlighted by the landmark approval of AMVUTTRA for ATTR-CM in the U.S., which drove total net product revenues of nearly $3 billion, or 81% growth year-over-year, and propelled us to profitability. We also achieved great progress across our portfolio, initiating three Phase 3 studies, expanding our pipeline with four proprietary CTAs, and launching a potential best-in-class enzymatic ligation-based RNAi manufacturing platform.”
— Yvonne Greenstreet, Q4 2025 Earnings Press Release
ALNY Earnings Trends
ALNY vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
ALNY EPS Trend
Earnings per share: estimate vs actual
ALNY Revenue Trend
Quarterly revenue: estimate vs actual
ALNY Quarterly Results
5 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q1 26 | — | $1.99 | — | $1.17B | +4.53% |
| Q4 25 BEAT FY | $1.24 | $1.25 | +0.81% | $1.10B | -5.22% |
| FY Full Year | $4.79 | $5.08 | +6.03% | $3.71B | -1.60% |
| Q3 25 BEAT | $1.75 | $2.90 | +66.12% | $1.25B | +28.22% |
| Q2 25 BEAT | $0.15 | $0.32 | +119.63% | $773.7M | +16.79% |
| Q4 23 BEAT FY | $-1.32 | $-0.77 | +41.67% | $439.7M | -0.10% |
| FY Full Year | $-3.47 | $-3.52 | -1.44% | $1.83B | -0.02% |